Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$7.54 -12.2%	$8.61	$6.51 ▼ $13.27	$7.99M	1.65	95,452 shs	3,218 shs
BDRX Biodexa Pharmaceuticals	$0.84 -0.9%	$1.04	$0.78 ▼ $20.25	$30.87M	1.17	1.19 million shs	364,278 shs
CGTX Cognition Therapeutics	$0.65 -3.8%	$0.37	$0.22 ▼ $2.54	$40.54M	0.88	4.23 million shs	3.13 million shs
KALA KALA BIO	$5.74 -3.9%	$4.51	$2.92 ▼ $11.20	$37.04M	-1.88	50,071 shs	42,843 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	0.00%	-15.19%	-15.23%	-0.84%	-8.45%
BDRX Biodexa Pharmaceuticals	0.00%	-3.36%	-18.00%	-40.94%	+84,459,900.00%
CGTX Cognition Therapeutics	0.00%	+15.26%	+133.57%	+75.62%	-65.94%
KALA KALA BIO	0.00%	-1.88%	+35.38%	+66.38%	-23.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXN Addex Therapeutics	1.7686 of 5 stars	3.5	3.0	0.0	0.0	0.8	0.6
BDRX Biodexa Pharmaceuticals	0.0681 of 5 stars	0.0	3.0	0.0	0.0	0.0	0.0
CGTX Cognition Therapeutics	3.1317 of 5 stars	3.5	3.0	0.0	3.7	1.7	0.6
KALA KALA BIO	3.8339 of 5 stars	3.5	2.0	4.4	1.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	3.00	Buy	$30.00	297.88% Upside
BDRX Biodexa Pharmaceuticals	0.00	N/A	N/A	N/A
CGTX Cognition Therapeutics	3.00	Buy	$2.83	333.23% Upside
KALA KALA BIO	3.00	Buy	$13.00	126.48% Upside

Current Analyst Ratings Breakdown

Latest ADXN, CGTX, KALA, and BDRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	KALA KALA BIO	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$460K	17.37	N/A	N/A	$10.37 per share	0.73
BDRX Biodexa Pharmaceuticals	$470K	65.66	N/A	N/A	$0.29 per share	2.91
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.31 per share	N/A
KALA KALA BIO	$3.89M	9.52	N/A	N/A	$2.02 per share	2.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	$8.02M	-$0.34	N/A	∞	N/A	3,584.49%	-54.27%	-49.15%	9/1/2025 (Estimated)
BDRX Biodexa Pharmaceuticals	-$7.32M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	-$33.97M	-$0.74	N/A	N/A	N/A	N/A	-194.42%	-115.14%	8/6/2025 (Estimated)
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)

Latest ADXN, CGTX, KALA, and BDRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CGTX Cognition Therapeutics	-$0.11	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	KALA KALA BIO	-$1.82	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	CGTX Cognition Therapeutics	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	3.02	3.02
BDRX Biodexa Pharmaceuticals	0.01	1.75	1.75
CGTX Cognition Therapeutics	N/A	2.09	2.09
KALA KALA BIO	3.19	1.99	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
BDRX Biodexa Pharmaceuticals	17.51%
CGTX Cognition Therapeutics	43.35%
KALA KALA BIO	24.61%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
BDRX Biodexa Pharmaceuticals	0.34%
CGTX Cognition Therapeutics	14.40%
KALA KALA BIO	8.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.06 million	901,000	Not Optionable
BDRX Biodexa Pharmaceuticals	20	36.54 million	36.42 million	Not Optionable
CGTX Cognition Therapeutics	20	61.99 million	53.07 million	Not Optionable
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable

ADXN, CGTX, KALA, and BDRX Headlines

Recent News About These Companies

LADENBURG THALM/SH SH Initiates Coverage on KALA BIO (NASDAQ:KALA)

July 14, 2025 | americanbankingnews.com

KALA BIO (NASDAQ:KALA) Raised to "Hold" at Wall Street Zen

July 14, 2025 | americanbankingnews.com

KALA Bio completes enrollment of CHASE clinical trial

July 12, 2025 | ophthalmologytimes.comO

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial ...

July 11, 2025 | morningstar.comM

KALA BIO Completes Patient Enrollment in CHASE Phase 2b Trial ... - Nasdaq

July 11, 2025 | nasdaq.com

KALA BIO Inc. (KALA) Stock Price Today - WSJ - The Wall Street Journal

July 10, 2025 | wsj.com

KALA BIO, Inc.: KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

July 9, 2025 | finanznachrichten.de

Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial

July 9, 2025 | tipranks.com

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

July 9, 2025 | globenewswire.com

Kala Bio Inc Valuation - Morningstar

July 8, 2025 | morningstar.comM

KALA BIO, Inc. (KALA) - Yahoo Finance

July 1, 2025 | finance.yahoo.com

KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $14,560.31 in Stock

June 27, 2025 | insidertrades.com

Mary Reumuth Sells 2,850 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

June 5, 2025 | insidertrades.com

KALA BIO to Present at Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | finance.yahoo.com

Chief Minister cancels programme over unauthorised nature of venue

April 20, 2025 | thehindu.com

KALA BIO: Q4 Earnings Snapshot

March 31, 2025 | timesunion.comT

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 31, 2025 | markets.businessinsider.com

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

February 26, 2025 | finance.yahoo.com

Kala Bio announces CEO departure, appoints interim leader

February 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN, CGTX, KALA, and BDRX Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$7.54 -1.05 (-12.22%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$7.90 +0.36 (+4.77%)

As of 07/18/2025 06:38 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Biodexa Pharmaceuticals NASDAQ:BDRX

$0.84 -0.01 (-0.87%)

Closing price 07/18/2025 03:58 PM Eastern

Extended Trading

$0.86 +0.02 (+1.82%)

As of 07/18/2025 07:59 PM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Cognition Therapeutics NASDAQ:CGTX

$0.65 -0.03 (-3.82%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.66 +0.01 (+1.38%)

As of 07/18/2025 07:57 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

KALA BIO NASDAQ:KALA

$5.74 -0.23 (-3.85%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.78 +0.04 (+0.78%)

As of 07/18/2025 06:42 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time